by Deborah Erickson
In 1985, Schwarz Pharma AG of Monheim, Germany was a private, family-owned business. The company still sold some of the products introduced upon its founding immediately after World War...
Schwarz Pharma's Middle Way
When the branded generics that long sustained Schwarz Pharma began losing value, and former Big Pharma partners took on their own distribution, the firm realized it must change. The mid-sized European company determined to aggressively in-license products and also began looking for companies to acquire. To fuel its aspirations, Schwarz made an unusual move for a family-owned European company; it issued public stock as a way to get cash and acquisition currency.
More from Business Strategy
More from In Vivo
• By
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
• By
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
• By
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.